Search - tctmd.com

Displaying 121 - 140 of 143

Sort: Relevancy | Date

Presentation TCT 2014

DCB ONLY and Vascular Restoration: Insights from Intracoronary OCT Human Studies

Presenter: Robert A. Byrne, Bruno Scheller, Francesco Liistro, Tudor C Poerner

September 13, 2014

Presentation PCI Outcomes 2014

The Thoughtful Approach to Recurrent DES Restenosis

Presenter: Robert A. Byrne

March 28, 2014

Presentation TCT 2013

ISAR DESIRE III Trial Update

Presenter: Robert Byrne

October 31, 2013

News Conference News TCT 2013

Thrombectomy Fails to Reduce Microvascular Obstruction in Non-STEMI

October 31, 2013

Presentation TCT 2013

Frequency and Time Course of DES Restenosis and Stent Thrombosis: Latest Insights from Randomized Trials and the "Real World"

Presenter: Robert Byrne

October 28, 2013

Presentation TCT 2013

The Challenge of Controlling Drug Dose and Elution from a Metallic Surface Without a Polymer

Presenter: Robert Byrne

October 27, 2013

News Conference News EuroPCR 2013

DESolve Nx: Bioresorbable DES Shows Positive Results at 6 Months

Jason Kahn

May 21, 2013

Presentation

Paclitaxel-Eluting Balloons, Paclitaxel-Eluting Stents, and Balloon Angioplasty in Patients with Restenosis After DES Implantation

Presenter: Robert A. Byrne

February 07, 2013

News Daily News

ISAR-DESIRE 3 Published: Paclitaxel-Eluting Balloons Match PES for DES Restenosis

Caitlin E. Cox

February 07, 2013

Presentation TCT 2013

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Presenter: Salvatore Cassese, Robert Byrne, Tomohisa Tada, Lamin King, Adnan Kastrati

January 31, 2013

Presentation TCT 2013

Restenosis after coronary stenting in 10,004 patients with follow-up angiography

Presenter: Salvatore Cassese, Robert Byrne, Julinda Mehilli, Stephanie Schulz, Tomohisa Tada, Lamin King, Susanne Pinieck, Albert Sch?mig, Adnan Kastrati

January 31, 2013

Presentation TCT 2013

Neointimal growth patterns after between biodegradable polymer biolimus-eluting or permanent polymer everolimus-eluting stent implantation assessed with newly developed...

Presenter: Tomohisa Tada, Adnan Kastrati, Robert Byrne, Tibor Schuster, Rezarta Cuni, Lamin King, Salvatore Cassese, Michael Joner, Steffen Massberg, Albert Sch?mig, Julinda Mehilli

January 31, 2013

Presentation TCT 2013

Bare-nitinol stent versus paclitaxel-coated balloon for femoro-popliteal revascularization. An adjusted indirect comparison meta-analysis of randomized trials

Presenter: Salvatore Cassese, Robert Byrne, Ilka Ott, Tareq Ibrahim, Tomohisa Tada, Lamin King, Adnan Kastrati, Massimiliano Fusaro

January 31, 2013

Presentation TCT 2012

Case 3: Management of Late Restenosis Due to Neoatherosclerosis with Plaque Rupture

Presenter: Robert Byrne

October 26, 2012

Presentation TCT 2012

ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of Limus-Eluting Coronary Stents

Presenter: Robert Byrne

October 26, 2012

News Conference News ACC 2012

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

L.A. McKeown

March 26, 2012

Presentation ACC 2012

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Presenter: Robert A. Byrne

March 24, 2012

News Conference News

Efficacy of SES for In-stent Restenosis Dependent on Original Stent Type

November 07, 2011

News Conference News

Evidence of Late Catch-up After DES ‘Unequivocal’

November 06, 2011

News Daily News

Long-term Outcomes Similar for Biodegradable-Polymer, Permanent-Polymer DES

September 12, 2011

Advertisement

DCB ONLY and Vascular Restoration: Insights from Intracoronary OCT Human Studies

The Thoughtful Approach to Recurrent DES Restenosis

ISAR DESIRE III Trial Update

Thrombectomy Fails to Reduce Microvascular Obstruction in Non-STEMI

Frequency and Time Course of DES Restenosis and Stent Thrombosis: Latest Insights from Randomized Trials and the "Real World"

The Challenge of Controlling Drug Dose and Elution from a Metallic Surface Without a Polymer

DESolve Nx: Bioresorbable DES Shows Positive Results at 6 Months

Paclitaxel-Eluting Balloons, Paclitaxel-Eluting Stents, and Balloon Angioplasty in Patients with Restenosis After DES Implantation

ISAR-DESIRE 3 Published: Paclitaxel-Eluting Balloons Match PES for DES Restenosis

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Restenosis after coronary stenting in 10,004 patients with follow-up angiography

Neointimal growth patterns after between biodegradable polymer biolimus-eluting or permanent polymer everolimus-eluting stent implantation assessed with newly developed...

Bare-nitinol stent versus paclitaxel-coated balloon for femoro-popliteal revascularization. An adjusted indirect comparison meta-analysis of randomized trials

Case 3: Management of Late Restenosis Due to Neoatherosclerosis with Plaque Rupture

ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of Limus-Eluting Coronary Stents

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Efficacy of SES for In-stent Restenosis Dependent on Original Stent Type

Evidence of Late Catch-up After DES ‘Unequivocal’

Long-term Outcomes Similar for Biodegradable-Polymer, Permanent-Polymer DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content